AstraZeneca PLC Cash Flow Conversion Efficiency
AstraZeneca PLC cash flow conversion efficiency. Based on the latest financial reports, AstraZeneca PLC (AZNN) has a cash flow conversion efficiency ratio of 0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$2.34 Billion ≈ $134.78 Million USD) by net assets (MX$48.72 Billion ≈ $2.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AstraZeneca PLC (2014–2025)
Cash flow conversion efficiency of AstraZeneca PLC from 2014 to 2025. This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AZNN stock price for real-time trading data and today's change.
AstraZeneca PLC Cash Flow Conversion Ratio Explained
AstraZeneca PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency. Also see AZNN market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Caterpillar Inc
NYSE:CAT
|
0.168x |
|
Morgan Stanley
NYSE:MS
|
-0.062x |
|
Morgan Stanley
SA:MSBR34
|
-0.030x |
|
Philip Morris International Inc
NYSE:PM
|
-0.825x |
|
General Electric Company
SA:GEOO34
|
0.179x |
|
Lam Research Corp
NASDAQ:LRCX
|
0.108x |
|
Royal Bank of Canada
TO:RY
|
0.026x |
|
AstraZeneca PLC
NASDAQ:AZN
|
0.071x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (2014–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 2014 to 2025. Review AstraZeneca PLC (AZNN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$48.72 Billion ≈ $2.80 Billion |
MX$14.57 Billion ≈ $838.80 Million |
0.299x | +3.09% |
| 2024-12-31 | MX$40.87 Billion ≈ $2.35 Billion |
MX$11.86 Billion ≈ $682.60 Million |
0.290x | +9.68% |
| 2023-12-31 | MX$39.17 Billion ≈ $2.25 Billion |
MX$10.36 Billion ≈ $596.39 Million |
0.265x | -0.03% |
| 2022-12-31 | MX$37.06 Billion ≈ $2.13 Billion |
MX$9.81 Billion ≈ $564.45 Million |
0.265x | +74.37% |
| 2021-12-31 | MX$39.29 Billion ≈ $2.26 Billion |
MX$5.96 Billion ≈ $343.17 Million |
0.152x | -50.54% |
| 2020-12-31 | MX$15.64 Billion ≈ $899.97 Million |
MX$4.80 Billion ≈ $276.18 Million |
0.307x | +50.87% |
| 2019-12-31 | MX$14.60 Billion ≈ $840.00 Million |
MX$2.97 Billion ≈ $170.87 Million |
0.203x | +9.12% |
| 2018-12-31 | MX$14.04 Billion ≈ $808.24 Million |
MX$2.62 Billion ≈ $150.67 Million |
0.186x | -13.30% |
| 2017-12-31 | MX$16.64 Billion ≈ $957.75 Million |
MX$3.58 Billion ≈ $205.91 Million |
0.215x | -13.54% |
| 2016-12-31 | MX$16.67 Billion ≈ $959.31 Million |
MX$4.14 Billion ≈ $238.55 Million |
0.249x | +38.46% |
| 2015-12-31 | MX$18.51 Billion ≈ $1.07 Billion |
MX$3.32 Billion ≈ $191.30 Million |
0.180x | -50.01% |
| 2014-12-31 | MX$19.65 Billion ≈ $1.13 Billion |
MX$7.06 Billion ≈ $406.19 Million |
0.359x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more